Disease Detail

ID DOID:80147
Name lymphoblastic lymphoma
Definition A lymphoma that has_material_basis_in immature malignant lymphocytes (lymphoblasts) committed to the B-cell or T-cell lineage and located_in primarily lymph nodes or located_in extranodal sites.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma lymphoblastic lymphoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Ibrutinib + VLX1570 lymphoblastic lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00501826 Phase II Nelarabine + Pegaspargase + Venetoclax Cyclophosphamide + Dexamethasone + Doxorubicin + Nelarabine + Pegaspargase + Venetoclax + Vincristine Mercaptopurine + Methotrexate + Prednisone + Venetoclax + Vincristine Cytarabine + Methotrexate + Nelarabine + Pegaspargase + Venetoclax Methotrexate + Pegaspargase + Venetoclax Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Active, not recruiting
NCT02879643 Phase I Dexamethasone + Methotrexate + Pegaspargase + Vincristine sulfate liposome Dexamethasone + Mercaptopurine + Methotrexate + Vincristine sulfate liposome Dexamethasone + Methotrexate + Mitoxantrone + Pegaspargase + Vincristine sulfate liposome Vincristine Sulfate Liposome Injection (Marqibo) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL Recruiting
NCT02906371 Phase I Tocilizumab Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome Active, not recruiting
NCT03023046 Phase II Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting
NCT03117751 Phase II Cyclophosphamide Vincristine Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting
NCT03136146 Phase II Cyclophosphamide Bortezomib Etoposide Rituximab Ofatumumab Clofarabine Pegfilgrastim Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) Recruiting
NCT03328104 Phase I Cyclophosphamide + Etoposide + Everolimus + Nelarabine AflacLL1602 ENCERT Recruiting
NCT03349281 Phase I Dexamethasone + Doxorubicin + MLN4924 + Pegaspargase + Vincristine Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia Recruiting
NCT03792256 Phase I Cytarabine + Hydrocortisone + Methotrexate Cytarabine + Doxorubicin + Palbociclib + Pegaspargase + Prednisone + Vincristine Methotrexate Cytarabine + Doxorubicin + Palbociclib + Pegaspargase + Prednisolone + Vincristine Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) Recruiting
NCT03962465 Phase I Daunorubicin + inotuzumab ozogamicin + Pegaspargase + Prednisone + Vincristine Daunorubicin + inotuzumab ozogamicin + Prednisone + Vincristine Cytarabine Methotrexate Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001) Not yet recruiting